Atlas Trials

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Clinical trial NCT02437422 · COMPLETED

Trial details

NCT number
NCT02437422
Sponsor
Prolong Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Renal Insufficiency, Chronic
Start date
2015-06-05
Primary completion
2015-11-18
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.